"Efficacy, Safety and Tolerability of Fixed Dose Combination of Cephalexin Extended Release and Clavulanate Potassium Tablets in the Treatment of Uncomplicated Skin and Soft Tissue Infections"

Ranbaxy Laboratories Ltd10 个研究点分布在 1 个国家目标入组 100 人开始时间: 2011年1月30日最近更新: 2013年3月14日

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 100
试验地点: 10
主要终点: Investigator assessed clinical outcome in clinically evaluable subjects

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is an open-label, non-comparative study with an objective to compare the Efficacy, Safety and Tolerability of Fixed Dose Combination of Cephalexin Extended Release and Clavulanate Potassium Tablets in the Treatment of Uncomplicated Skin and Soft Tissue Infections. The study is to be conducted at 10 centres all over India. The primary outcome is Investigator assessed clinical outcome in clinically evaluable subjects at test-of-cure visit (7-9 days after end of treatment) and secondary outcome is Microbiological outcome in all microbiologically evaluable subjects at test-of-cure visit (7-9 days after end of treatment).

研究设计

研究类型: Interventional
分配方式: Not Applicable
盲法: Not Applicable

入排标准

年龄范围: 12.00 Year(s) 至 99.00 Year(s)（—）
性别: All

入选标准

•Subjects who have given written informed consent/assent to participate in the study.
•Additional written informed consent will be taken from parents/LAR (as applicable) in case assent is taken from subjects aged less then 18 yrs.
•Subjects of either sex, aged more then or equal to 12 years and weighing more then or equal to 40 kg.
•Subjects with diagnosis of uncomplicated skin and soft tissue infections with an onset of infection less then 7 days, judged to require antibiotic therapy.
•Acceptable clinical diagnoses of uSSTIs include, but are not limited to: simple abscess, impetigo, furunculosis, cellulitis, carbuncles, erysipelas, folliculitis, paronychia, superficial wound infections (traumatic, post surgical).
•The uncomplicated skin and soft tissue infection is accompanied by 2 or more of the following local signs and symptoms with or without systemic features of infection: pain/tenderness, swelling, erythema, localized warmth, purulent drainage/discharge, induration, regional lymph node swelling or tenderness
•Subjects who have positive pre-treatment culture from microbiological specimen obtained from the skin lesions.
•Culture will be defined as positive if at least one of the following skin pathogens is identified: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli Note:Â Microbiological specimens (e.g., pus aspirate, swabs etc.
•from the site of infection) as appropriate will be collected for microbiological analysis from all subjects as per the Hospital/Clinic protocol or practice Treatment will be initiated before the results of culture are available.
•However, when these results become available, suitability of the subject for inclusion in the study will be reviewed at visit 2 (Day 3-5).
•Subjects with sterile culture or negative culture for predefined pathogens will be withdrawn from the study.
•Subjects showing clinical improvement with isolate(s) resistant to study drug will be allowed to continue in the study at the discretion of the investigator.
•Subjects who have persistence or worsening of signs and symptoms or appearance of new signs and symptoms associated with skin lesions after 3 days of treatment will be considered as treatment failures and will be withdrawn from the study Surgical intervention (drainage, incision of the tissue swelling etc.) as appropriate will be done as per the discretion of the investigator.

排除标准

•Subjects with history of hypersensitivity to cephalexin, other cephalosporins, penicillins or other beta-lactam class of antibiotics, clavulanate potassium or other beta-lactamase inhibitors or any of the excipients* of study formulation
•Subjects requiring hospitalization or parenteral antibiotic treatment
•Subjects who have received antibiotic treatment for >/= 24 hours during the 72 hours prior to enrollment in the study (unless treatment failure was documented)
•Subjects with a concomitant infection that needs an additional oral or topical anti-microbial agent or which in the opinion of the investigator could preclude evaluation of response to study medication
•Subject with a complicated skin and soft tissue infection as judged by the investigator
•A chronic or underlying skin condition at the site of infection (e.g., a secondarily infected atopic dermatitis or eczema) or infections involving prosthetic materials (e.g., catheter tunnel infections, orthopedic instruments)
•Subjects with secondarily infected thermal injury (burns) or acne vulgaris
•Subjects with solitary furuncle, involvement of perianal area, facial cellulitis or cellulitis associated with animal or human bite (except insect bite), diabetic foot ulcers or decubitus ulcers (bed sores) or significant peripheral vascular disease
•Subjects with skin and soft tissue infection with suspected or proven contiguous bone, nail bed or scalp involvement
•Subjects with clinically significant cardiovascular, hematological (including subjects with bleeding diathesis, on anticoagulant therapy or with vitamin K deficiency), renal, hepatic, endocrinal (including subjects with history of diabetes mellitus), pulmonary, urogenital, gastrointestinal, progressive neurological illness (including subjects with history of epilepsy) or psychiatric illness or any other medical condition that might put the subject at greater risk during study participation
•Pregnant or breast feeding women or women of child-bearing potential not using medically acceptable methods of contraception or women with positive urine pregnancy test (UPT) at screening
•Subjects with a history of drug or alcohol abuse
•Subjects unwilling or unable to comply with the study procedures
•Subjects who have participated in another investigational study in the previous 3 months prior to enrollment in this study
•Subjects with history of immuno-suppression or on chronic immunosuppressive therapy or diagnosis of acquired immunodeficiency syndrome (AIDS).
•Subjects with SGOT/AST or SGPT/ALT > 3.0 times upper limit of normal (ULN) or alkaline phosphatase or serum bilirubin >2.0 times ULN or serum creatinine >2.0 mg/dL*Microcrystalline cellulose; sodium starch glycolate; colloidal anhydrous silica; magnesium stearate; hypromellose; hydroxypropyl cellulose; talc; opadry; polyethylene glycol.

结局指标

主要结局

Investigator assessed clinical outcome in clinically evaluable subjects

时间窗: At test-of-cure visit (7-9 days after end of treatment)

次要结局

Microbiological outcome in all microbiologically evaluable subjects(At test-of-cure visit (7-9 days after end of treatment))

研究者

发起方

Ranbaxy Laboratories Ltd

申办方类型

Pharmaceutical industry-Global

研究点 (10)

Loading locations...

相似试验

尚未招募

3 期

A clinical trial to study the efficacy and safety of fixed dose combination in the treatment of gastroesophageal reflux disease.

CTRI/2012/04/002575Sun Pharmaceutical Industries Ltd200

招募中

4 期

A Clinical Study to Evaluate the Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitis

CTRI/2022/06/043453Win Medicare Pvt Ltd220

已完成

1 期

A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate DrugsHealthy Volunteers

NCT03787017Handok Inc.36

已完成

1 期

A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mgHealthy Volunteers

NCT03787043Handok Inc.30

已完成

3 期

Cefozopran injection in treatment of community acquired pneumonia

CTRI/2013/02/003366Ranbaxy Research Laboratories100